Mirum (MIRM) Soars on Interim Data From Liver Disease Studies [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
evaluated its oral ileal bile acid transporter inhibitor, volixibat, for treating patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The phase IIb VISTAS study investigated volixibat for the treatment of PSC, while the phase IIb VANTAGE study evaluated volixibat for the treatment of PBC. Interim data from the VANTAGE study showed that treatment with volixibat led to a statistically significant improvement in pruritus and a placebo-adjusted difference of -2.32 points in the primary endpoint of pruritus, as measured by the Adult ItchRO scale. Meanwhile, 75% of the patients who were treated with volixibat achieved more than 50% reduction in serum bile acids. Also, treatment with volixibat resulted in significant improvement in fatigue versus placebo at week 16. Based on the above mentioned interim data, the VANTAGE study will continue to investigate volixibat 20 mg twice daily. Shares of Mirum have risen 11.7% so far this year against the
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $16.00 price target on the stock.MarketBeat
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisGlobeNewswire
ACRV
Earnings
- 8/13/24 - Beat
ACRV
Sec Filings
- 9/16/24 - Form 8-K
- 8/23/24 - Form 4
- 8/16/24 - Form 4
- ACRV's page on the SEC website